11.31
-0.14 (-1.22%)
-0.14 (-1.22%)
Upgrade to Real-Time
Regular Market
| Volume | 164,014 |
|
|||||
| News | (1) | ||||||
| Day High | 11.40 | Low High |
|||||
| Day Low | 11.1581 | ||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc | AUPH | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| -0.14 | -1.22% | 11.31 | 09:51:17 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 11.21 | 11.1581 | 11.40 | 11.45 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 914 | 164,014 | $ 11.23 | $ 1,842,642 | - | 8.86 - 33.9715 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:51:17 | 10 | $ 11.34 | USD |
Period:
Draw Mode:
Aurinia Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.60B | 141.74M | 141.32M | $ 45.61M | $ - | -1.41 | -8.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 1.09M | 0.30% |
Aurinia Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AUPH Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.02 | 11.77 | 9.11 | 10.49 | 2,891,492 | 0.29 | 2.63% |
| 1 Month | 11.16 | 11.8699 | 8.86 | 10.64 | 2,466,126 | 0.15 | 1.34% |
| 3 Months | 16.17 | 16.30 | 8.86 | 11.58 | 2,963,424 | -4.86 | -30.06% |
| 6 Months | 29.00 | 30.44 | 8.86 | 16.12 | 3,351,126 | -17.69 | -61.0% |
| 1 Year | 12.21 | 33.9715 | 8.86 | 17.70 | 3,673,101 | -0.90 | -7.37% |
| 3 Years | 6.59 | 33.9715 | 3.52 | 15.75 | 2,592,562 | 4.72 | 71.62% |
| 5 Years | 7.07 | 33.9715 | 3.52 | 13.99 | 1,911,086 | 4.24 | 59.97% |
Aurinia Pharmaceuticals Description
| Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States. |